The Impact of Continuous Glucose Monitoring on Low Interstitial Glucose Values and Low Blood Glucose Values Assessed by Point-of-care Blood Glucose Meters: Results of a Crossover Trial
Open accessThe DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
Objective: In a randomized crossover trial the impact of continuous glucose monitoring (CGM) was tested on the occurrence of low blood glucose values measured by point of care (POC) measurement and on low glucose values measured by CGM in the interstitial fluid. Methods: A total of 41 type 1 diabetic patients (age 42.0 ± 11.4 years, diabetes duration 15.3 ± 10.1 years, A1c 8.2 ± 1.4%) used a CGM system (Dexcom SEVEN PLUS system) twice. In first study phase (CGM blind), patients were blind regarding the CGM current glucose levels and were not alerted when critical glucose values were reached. In the second phase (CGM real time), patients had access to current glucose levels and were alerted if critical glucose values were reached. Results: During CGM real time the proportion of hypoglycemic POC blood glucose values were significantly reduced (7.5 ± 5.6% vs 10.1 ± 7.5%; P = .04), whereas the proportion of euglycemic blood glucose values were significantly enhanced (73.7 ± 18.3% vs 68.3 ± 12.1%; P = .01). The duration of low glucose periods in the interstitial fluid was significantly lower in the CGM real time phase (125 ± 89 vs 181 ± 125 minutes per day; P = .005). The time until a low blood glucose was detected by POC measurement was shortened by 33.2 ± 76.1 minutes ( P = .03). Conclusion: The study demonstrated that CGM is able to not only reduce duration of hypoglycemia measured by CGM in interstitial fluid, but also reduce the proportion of low POC blood glucose measurements. In addition, hypoglycemia can be detected earlier.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Real-time CGM studies can be divided into studies with elevated A1C with the primary end point of A1C reduction and studies with A1C near target with the primary end point of reduction in hypoglycemia (98, 109-124).”
From 6. Glycemic Targets: Standards of Care in Diabetes—2023 (2023) · cites this paper as [114]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Most randomized controlled trials (RCTs) in adults with type 1 diabetes show that rt-CGM leads to lower HbA 1c (156-159) and reduced time in the hypoglycemic range (160,161).”
From Guidelines and Recommendations for Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus (2023) · cites this paper as [160]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
An Introduction to Medical Statistics.
(1931) · Journal of the American Medical Association · doi:10.1001/jama.1931.02730150055037 · Cited by 2,084
Continuous glucose monitoring and intensive treatment of type 1 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0805017 · Cited by 1,559
Threshold-based insulin-pump interruption for reduction of hypoglycemia
Bergenstal, R. M., Klonoff, D. C., Garg, S. K., Bode, B. W., Meredith, M., Slover, R. H., Ahmann, A. J., Welsh, J. B., Lee, S. W., & Kaufman, F. R. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1303576 · Cited by 652
Pickup, J. C., Freeman, S. C., & Sutton, A. J. (2011) · BMJ · doi:10.1136/bmj.d3805 · Cited by 541 · cited 8×
“However, the avoidance of severe hypoglycemia as a clinical endpoint by means of CGM could not be demonstrated.(1,2) In contrast to the outcomes concerning the reduction of hyperglycemia, which could be corroborated by independent measures (eg, A1c) or episodes of ketoacidosis,(1,2) the results regarding minimizing hy…”
BackgroundMethodResultInfluentialthe SWITCH Study Group, Battelino, T., Conget, I., Olsen, B., Schütz-Fuhrmann, I., Hommel, E., Hoogma, R., Schierloh, U., Sulli, N., & Bolinder, J. (2012) · Diabetologia · doi:10.1007/s00125-012-2708-9 · Cited by 494 · cited 3×
“There is convincing evidence that the use of CGM is capable of reducing exposure to hypoglycemic glucose values measured in the interstitial fluid.(1,3,14,15) However, these results mainly rely on the CGM glucose measurement itself.”
MethodResultInfluentialAn Introduction to Medical Statistics.
Oldham, P. D., & Lancaster, H. O. (1974) · Journal of the Royal Statistical Society. Series A (General) · doi:10.2307/2344722 · Cited by 494
Effect of Continuous Glucose Monitoring on Hypoglycemia in Type 1 Diabetes
Battelino, T., Phillip, M., Bratina, N., Nimri, R., Oskarsson, P., & Bolinder, J. (2011) · Diabetes Care · doi:10.2337/dc10-1989 · Cited by 490 · cited 1×
“There is convincing evidence that the use of CGM is capable of reducing exposure to hypoglycemic glucose values measured in the interstitial fluid.(1,3,14,15) However, these results mainly rely on the CGM glucose measurement itself.”
MethodNocturnal Glucose Control with an Artificial Pancreas at a Diabetes Camp
Phillip, M., Battelino, T., Atlas, E., Kordonouri, O., Bratina, N., Miller, S., Biester, T., Avbelj Stefanija, M., Muller, I., Nimri, R., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1206881 · Cited by 435
Improvement in Glycemic Excursions With a Transcutaneous, Real-Time Continuous Glucose Sensor
Garg, S., Zisser, H., Schwartz, S., Bailey, T., Kaplan, R., Ellis, S., & Jovanovic, L. (2006) · Diabetes Care · doi:10.2337/diacare.29.01.06.dc05-1686 · Cited by 433 · cited 1×
“There is convincing evidence that the use of CGM is capable of reducing exposure to hypoglycemic glucose values measured in the interstitial fluid.(1,3,14,15) However, these results mainly rely on the CGM glucose measurement itself.”
MethodContinuous glucose monitoring systems for type 1 diabetes mellitus
Langendam, M., Luijf, Y. M., Hooft, L., DeVries, J. H., Mudde, A. H., & Scholten, R. J. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008101.pub2 · Cited by 262 · cited 7×
“However, the avoidance of severe hypoglycemia as a clinical endpoint by means of CGM could not be demonstrated.(1,2) In contrast to the outcomes concerning the reduction of hyperglycemia, which could be corroborated by independent measures (eg, A1c) or episodes of ketoacidosis,(1,2) the results regarding minimizing hy…”
BackgroundResultInfluential
Research works printed but not linked: 2
- Langendam M, 2012, Cochrane Database Syst Rev, 1, CD008101
- 10.1177/193229681300700406 · DOI
Cited by
6. Glycemic Targets: Standards of Medical Care in Diabetes—2022
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s006 · Cited by 1,403
6. Glycemic Targets: Standards of Medical Care in Diabetes—2021
American Diabetes Association (2021) · Diabetes Care · doi:10.2337/dc21-s006 · Cited by 847
6. Glycemic Targets: Standards of Medical Care in Diabetes—2020
American Diabetes Association (2020) · Diabetes Care · doi:10.2337/dc20-s006 · Cited by 744
6. Glycemic Targets: Standards of Care in Diabetes—2023
ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Hilliard, M. E., Isaacs, D., Johnson, E. L., et al. (2023) · Diabetes Care · doi:10.2337/dc23-s006 · Cited by 684
Martens, T., Beck, R. W., Bailey, R., Ruedy, K. J., Calhoun, P., Peters, A. L., Pop-Busui, R., Philis-Tsimikas, A., Bao, S., Umpierrez, G., et al. (2021) · JAMA · doi:10.1001/jama.2021.7444 · Cited by 543
“Participants with ≥1 adverse events 10 (9) 5 (9)”
Background
Metadata
- Authors
- Hermanns, N., Schumann, B., Kulzer, B., & Haak, T.
- Affiliations
- German Diabetes Center Mergentheim (DE)
- Venue
- Journal of Diabetes Science and Technology
- Publisher
- SAGE Publications
- Published
- 2014-02-21
- Volume
- 8
- Issue
- 3
- Pages
- 516-522
- ISSN
- 1932-2968 (ISSN-L)
- PMC
- PMC4455434
- OpenAlex
- W2128232384
- Cited by
- 39
- References
- 19
- Citations by year
- 2025: 4 · 2024: 3 · 2023: 5 · 2022: 4 · 2021: 9 · 2020: 5 · 2019: 3 · 2018: 1 · 2017: 3 · 2016: 2
- FWCI
- 1.34
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- Journal of Diabetes Science and Technology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- continuous glucose monitoring, hypoglycemia, type 1 diabetes, interstitial glucose, hypoglycemia detection, hypoglycemia duration
- MeSH terms
- Adult, Blood Glucose, Diabetes Mellitus, Type 1, Equipment Design, Germany, Glycated Hemoglobin, Humans, Hypoglycemia, Hypoglycemic Agents, Insulin, Middle Aged, Predictive Value of Tests, Blood Glucose Self-Monitoring, Reproducibility of Results, Biomarkers, Cross-Over Studies, Point-of-Care Systems, Early Diagnosis, Extracellular Fluid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Impact of Continuous Glucose Monitoring on Low Interstitial Glucose Values and Low Blood Glucose Values Assessed by Point-of-care Blood Glucose Meters: Results of a Crossover Trial. https://app.cochat.ai/papers/10.1177/1932296814524105
- The paper
- Hermanns, N., Schumann, B., Kulzer, B., & Haak, T. (2014). The Impact of Continuous Glucose Monitoring on Low Interstitial Glucose Values and Low Blood Glucose Values Assessed by Point-of-care Blood Glucose Meters: Results of a Crossover Trial. Journal of Diabetes Science and Technology. https://doi.org/10.1177/1932296814524105
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.